Hem › Akut bifentypisk leukemi › Kentucky › Lexington
Kliniska studier för Akut bifentypisk leukemi i Lexington, KY
3 studier för Akut bifentypisk leukemi söker deltagare vid platser i och runt Lexington (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
RekryterarFas 2
- University of Kentucky/Markey Cancer Center, Lexington
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
RekryterarFas 3
- University of Kentucky/Markey Cancer Center, Lexington
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RekryterarFas 1/2
- University of Kentucky/Markey Cancer Center, Lexington
Akut bifentypisk leukemi-studier i andra städer
- Seattle, WA15 studier
- Houston, TX11 studier
- New York City, NY10 studier
- Atlanta, GA9 studier
- Durham, NC8 studier
- Memphis, TN7 studier
- Chicago, IL7 studier
- Charlotte, NC6 studier
- Baldwin Park, CA6 studier
- Aurora, CO6 studier
- Dallas, TX6 studier
- Philadelphia, PA6 studier
Andra studier i Lexington
- Icke-småcellig lungcancer23 studier
- Lungcancer18 studier
- Äggstockscancer16 studier
- Prostatacancer14 studier
- Cancer (alla typer)14 studier
- Bröstcancer14 studier
- Metastaserande cancer11 studier
- Kolorektal cancer11 studier
- Hjärtsvikt11 studier
- Melanom10 studier
- Akut myeloid leukemi10 studier
- Övervikt10 studier
Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.